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Background: Iron, an essential element for bacterial life.
Native FepB functions in the periplasm to facilitate the
transfer of ferric enterobactin through the two- protein
inner membrane channel FepDG into cytoplasm by FepC
catalyzed ATP hydrolysis. These data support the idea that
production of antibody against FepB may contribute to pro-
tection against gram negative bacteria. The present study
was designed to identify, produce and immunoactivate the
periplasmic binding protein, FepB from Escherichia coli
O157:H7
Methods: The gene coding for ferric enterobactin biding
protein from E. coli O157:H7 was ampliﬁed. This gene was
cloned and expressed as C-terminal His(6)-tagged protein.
Results: The SDS-PAGE analysis of the total protein
revealed only two distinct bands, with molecular masses of
31 kDa and 34 kDa. The Ni-NTA chromatography puriﬁed FepB
and the osmotically shocked periplasmic fraction of IPTG
induced cells showed only a single band of 31 kDa. Polyclonal
mouse antibody was raised against the recombinant protein
during 4 weeks after immunization. Western blot analysis
of the recombinant FepB with mouse antiserum revealed a
single band of 31 kDa. Polyclonal antibody raised against the
recombinant protein reacted with bacterial FepB.
Conclusion: Identiﬁcation and puriﬁcation of FepB helped
reveal its appropriate molecular mass. Reaction of the
recombinant FepB antiserum with bacterial FepB ﬁnds its
immunoactive contribution to protection against gram neg-
ative bacteria harbouring the FepB protein. The successful
production of antibody by periplasmic product of FepB gene
can ﬁnd a room for further research aimed at broad spec-
trum vaccines production.
doi:10.1016/j.ijid.2008.05.682
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Recombinant Omp28 (r-Omp28) from Brucella meliten-
sis produced in Escherichia coli was previously identiﬁed
as group 3 proteins. In this study, we evaluated the
immunogenicity of r-Omp28 in mice. This r-Omp28 was
injected intramuscularly in the mice with and without CpG
oligodeoxynucleotides (ODN). The booster was given on 3rd
week with the same antigenic preparation. Speciﬁc anti-
bodies to puriﬁed r-Omp28 were detected in mice sera
by western blotting and indirect ELISA (iELISA). In addi-
tion, isotype (IgG1 and IgG2a) speciﬁc antibodies were also
measured by iELISA. Cellular immune response was mea-
sured by lymphocyte proliferation assay (MTT assay) after
in vitro stimulation of spleenocytes by r-Omp28. Immu-
nization with r-Omp28 induced a vigorous immunoglobulin
G (IgG) response, with higher IgG1 than IgG2a. Whereas,
immunization of mice with rOmp28 +CpG induced IgG2a
dominated response, suggesting the induction of a T helper
1 (Th1) response by CpG ODN. Spleenocyte from immunized
mice showed signiﬁcant proliferative response (3 week post
booster), but it was higher (P < 0.05) in r-Omp28 +CpG than
r-Omp28 immunized mice. Our results indicate that r-Omp28
is a good immunogen, capable of inducing both humoral and
cellular immune response. The humoral response was biased
towards Th1 type when it was co-administered with CpG
ODN.
doi:10.1016/j.ijid.2008.05.683
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Lassa virus (LASV) is the cause of widespread human
infection in West Africa that occasionally develops into Lassa
Fever (LF) and is responsible for the deaths of thousands of
people each year. The ‘‘at risk’’ LASV sero-negative pop-
ulation in the region may be as high as 200million. In the
general population the case fatality rate is 1-2% and can be
as high as 15—30% among hospitalized patients. The sizeable
disease burden, numerous imported cases worldwide, and
possibility that LASV can be used as an agent of biological
warfare make a strong case for vaccine development.
Reassortant technology was used to make ML29 virus
encoding the major antigens (NP and GPC) of LASV and
the RNA polymerase and Z protein of Mopeia virus (MOPV),
a naturally attenuated virus genetically related to LASV.
Plaque puriﬁcation and restricted numbers of cell culture
passages resulted in eighteen mutations distinguishing the
ML29 genome from the parental LASV and MOPV strains.
These mutations additionally contributed to the attenuated
phenotype.
In the current study we evaluated safety, immunogenic-
ity, and efﬁcacy of the ML29 reassortant vaccine using
a recently-established human LF model in common mar-
mosets, Callithrix jacchus. We have shown that a single
injection of ML29 induced low, transient viremia and ML29
replicated at low or moderate levels in target tissues
depending on dose of the vaccination. Exposure of human
PBMC with ML29 and MOPV has been used as an additional
safety test. The gene expression patterns of ML29-exposed
cells and control, mock-exposed cells, clustered together
and maintained a signiﬁcant distance from the MOPV group.
A single ML29 vaccination induced speciﬁc and non-speciﬁc
immune responses and completely protected monkeys in
challenge experiments against fatal LF by induction of ster-
